Skip to content


  • Poster presentation
  • Open Access

Unleashing the power of anti-tumor CD4+ T cells: novel insights into the curative mechanisms of chemoimmunotherapy for cancer

  • 1 and
  • 1
Journal for ImmunoTherapy of Cancer20153 (Suppl 2) :P18

  • Published:


  • Metabolic Profile
  • Interferon Gamma
  • Adoptive Transfer
  • Tumor Rejection
  • Rational Combination


CD4+ T cells are critical mediators of anti-tumor immunity and orchestrate a broad range of immune responses against cancer. Previous studies from our lab and others have demonstrated that, adoptive transfer of tumor specific CD4+ T cells to lymphopenic hosts led to eradication of established tumors in mice models. Accumulating evidence from preclinical and clinical studies also suggest that CD4+ T cells in combination with chemotherapy can control tumor progression and recurrence. However, the molecular and cellular mechanisms by which tumor reactive CD4+ T cells eliminate a wide variety of tumors are not completely understood.


In this project, we set out to study the mechanisms underlying the therapeutic effect of chemo-immunotherapy in the form of cyclophosphamide (CTX) and tumor specific CD4+ T cells. Recent studies have revealed that combined effect of Th-1 cytokines, IFN-γ and TNF, drive both murine and human cancer cells in to senescence. In the present study we wanted to examine the specific roles of IFN-γ and TNF-α in the setting of chemoimmunotherapy and the contribution of other immune cells in the tumor microenvironment to tumor rejection beside the donor CD4+ T cells.


In a mouse model of colorectal cancer, we found that host-derived interferon gamma (IFN-γ) and expression of IFN-γR are critical components of CD4+T cell-mediated tumor rejection, whereas depletion of NK cells and macrophages separately did not compromise the therapeutic effect of the CTX and CD4+T cells regimen. In addition, IFN-γ appeared to drive tumor senescence and apoptosis in vivo, leading to a curative outcome. Furthermore, we analyzed the global metabolic profiling of tumor tissues at different time points before and after chemoimmunotherapy.


Our data suggests that CD4+T cells reprogram the metabolic profiling in tumor, tipping the balance towards progressive tumor regression. These findings may provide new insights into mechanisms of tumor rejection by CD4+ T cells, and may help develop more effective anti-tumor strategies based on a rational combination of chemotherapy and anti-tumor CD4+ T cells.

Authors’ Affiliations

Georgia Regents University, Augusta, GA, USA